Renal Progression
Cross-source consensus on Renal Progression from 1 sources and 5 claims.
1 sources · 5 claims
Comparisons
Evidence quality
Other
Highlighted claims
- The primary outcome defined renal progression as end-stage renal disease requiring renal replacement therapy, sustained eGFR decline of at least 30%, or persistent doubling of serum creatinine with low eGFR. — Lobeglitazone and the risk of renal progression in Korean patients with type 2 diabetes mellitus: a retrospective cohort study
- The adjusted hazard ratio versus metformin monotherapy was 0.84, with a 95% confidence interval from 0.58 to 1.21. — Lobeglitazone and the risk of renal progression in Korean patients with type 2 diabetes mellitus: a retrospective cohort study
- Kaplan-Meier analysis found no statistically significant cumulative renal progression difference in any treatment comparison. — Lobeglitazone and the risk of renal progression in Korean patients with type 2 diabetes mellitus: a retrospective cohort study
- The adjusted renal progression hazard ratios versus sulfonylurea plus metformin and DPP4 inhibitor plus metformin were not statistically significant. — Lobeglitazone and the risk of renal progression in Korean patients with type 2 diabetes mellitus: a retrospective cohort study
- Urinary albumin-to-creatinine ratio was excluded from the primary renal progression outcome because many patients lacked data. — Lobeglitazone and the risk of renal progression in Korean patients with type 2 diabetes mellitus: a retrospective cohort study